CONSHOHOCKEN, PA — Madrigal Pharmaceuticals (Nasdaq: MDGL) granted equity awards to 15 newly hired employees as the biotechnology company continues expanding operations around its approved liver disease treatment Rezdiffra and ongoing late-stage clinical programs.
The inducement awards, approved May 15 by the company’s independent compensation committee, covered a total of 5,308 restricted stock units issued under Madrigal’s 2025 Inducement Plan.
The grants were issued under Nasdaq inducement award rules that allow listed companies to offer equity compensation to new employees outside shareholder-approved stock plans as part of recruitment efforts.
The awards vest in four equal annual installments over four years, contingent on continued employment with the company.
Madrigal has been expanding commercial and clinical operations following the approval of Rezdiffra, the company’s treatment for metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced fibrosis.
The company is also conducting a Phase 3 outcomes study evaluating Rezdiffra in patients with compensated MASH cirrhosis, a more advanced stage of liver disease.
Competition within the metabolic and liver disease treatment market has intensified as pharmaceutical companies seek positions in what analysts view as a potentially multibillion-dollar therapeutic category tied to rising obesity and metabolic disease rates globally.
Madrigal stated the equity awards were granted as inducements material to the employees’ acceptance of employment with the company.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.